NCT04705844

Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)

Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Adalimumab (Humira) or Placebo in Patients With Mild-Moderate COVID-19

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Alachua Government Services, Inc. · Industry
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Clinical study of Humira (adalimumab) or placebo in subjects with mild-moderate COVID-19

Conditions

• Mild to Moderate COVID-19

Interventions

Type	Name	Description
DRUG	Adalimumab	adalimumab (160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen)
DRUG	Placebo	placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)

Timeline

• Start date: 2021-09-01
• Primary completion: 2022-09-01
• Completion: 2022-09-01
• First posted: 2021-01-12
• Last updated: 2022-03-03

Regulatory

• FDA-regulated drug study